JAKAFI XR Drug Patent Profile

Which patents cover Jakafi Xr, and when can generic versions of Jakafi Xr launch?

Jakafi Xr is a drug marketed by Incyte Corp and is included in one NDA. There are seventeen patents protecting this drug.

This drug has three hundred and eight patent family members in fifty countries.

The generic ingredient in JAKAFI XR is ruxolitinib phosphate. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ruxolitinib phosphate profile page.

DrugPatentWatch^® Generic Entry Outlook for Jakafi Xr

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 14, 2033. This may change due to patent challenges or generic licensing.

There have been five patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for JAKAFI XR

International Patents:	308
US Patents:	17
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for JAKAFI XR

US Patents and Regulatory Information for JAKAFI XR

JAKAFI XR is protected by forty-one US patents.

This potential generic entry date is based on patent 10,874,616.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Incyte Corp	JAKAFI XR	ruxolitinib phosphate	TABLET, EXTENDED RELEASE;ORAL	217180-002	May 1, 2026		RX	Yes	No	11,576,865		Y
Incyte Corp	JAKAFI XR	ruxolitinib phosphate	TABLET, EXTENDED RELEASE;ORAL	217180-001	May 1, 2026		RX	Yes	No	8,530,485		Y
Incyte Corp	JAKAFI XR	ruxolitinib phosphate	TABLET, EXTENDED RELEASE;ORAL	217180-004	May 1, 2026		RX	Yes	No	7,598,257		Y	Y
Incyte Corp	JAKAFI XR	ruxolitinib phosphate	TABLET, EXTENDED RELEASE;ORAL	217180-003	May 1, 2026		RX	Yes	No	11,744,832
Incyte Corp	JAKAFI XR	ruxolitinib phosphate	TABLET, EXTENDED RELEASE;ORAL	217180-004	May 1, 2026		RX	Yes	No	8,415,362		Y	Y
Incyte Corp	JAKAFI XR	ruxolitinib phosphate	TABLET, EXTENDED RELEASE;ORAL	217180-003	May 1, 2026		RX	Yes	No	7,598,257		Y	Y

International Patents for JAKAFI XR

When does loss-of-exclusivity occur for JAKAFI XR?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Costa Rica

Croatia

Cyprus

Denmark

Ecuador

Eurasian Patent Organization

European Patent Office

Hong Kong

Hungary

Israel

Japan

Lithuania

Malaysia

Mexico

New Zealand

Peru

Philippines

Poland

Portugal

San Marino

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering JAKAFI XR around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2008266183
Brazil	PI0814254
Canada	2689663
China	101932582
China	103524509
Colombia	6251256

Supplementary Protection Certificates for JAKAFI XR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1966202	PA2013002	Lithuania
1966202	8/2013	Austria		PRODUCT NAME: RUXOLITINIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/12/773/001-003 20120823
2455382	PA2017012	Lithuania		PRODUCT NAME: RUKSOLITINIBAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/12/773/001-006 20150311
1966202	2013/004	Ireland		PRODUCT NAME: RUXOLITINIB, OR A PHARMACEUTICALLY ACCEPTABLE SALT THREOF; REGISTRATION NO/DATE: EU/1/12/773/001-003 20120823
1966202	2013C/014	Belgium		PRODUCT NAME: RUXOLITINIB OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; AUTHORISATION NUMBER AND DATE: EU/1/12/773/001 20120828
1966202	448	Finland

JAKAFI XR (ruxolitinib extended-release) Investment Scenario and Fundamentals Analysis: Patent/IP, FDA status, launch economics, and generic or biosimilar risk

Last updated: July 4, 2026

JAKAFI XR is a ruxolitinib extended-release product within the JAKAFI portfolio. The investment case depends on (1) the durability of exclusivity and patent coverage for extended-release formulations and associated method-of-use claims, (2) whether the label drives sustained demand versus competitors in myelofibrosis and polycythemia vera, and (3) the timing and probability of generic substitution. The downside hinges on Paragraph IV filings against any Orange Book-listed XR-specific patents and on label or reimbursement erosion that could reduce unit demand before key exclusivity windows close.

What is JAKAFI XR (ruxolitinib extended-release) and how is it used clinically?

JAKAFI XR is an extended-release (XR) formulation of ruxolitinib, a Janus kinase (JAK) inhibitor. Ruxolitinib is used in hematologic myeloid disorders where JAK signaling drives disease activity, including:

Which indications does JAKAFI XR target in the US?

JAKAFI (immediate-release) is approved for:

• Myelofibrosis (intermediate-2 or high-risk; including primary myelofibrosis and post-polycythemia vera or post-essential thrombocythemia myelofibrosis)
• Polycythemia vera (inadequate response to or intolerance of hydroxyurea)

Because XR products are typically label-linked to the same disease areas as the parent IR product, the investment relevance is the XR label alignment: insurer and payer adoption is usually driven by whether XR offers dosing convenience or tolerability advantages without narrowing the responder population.

Why does XR matter for revenue?

XR can support:

• Lower dosing frequency versus IR regimens
• Improved adherence and persistence
• Potential differentiation with competitors through dosing convenience rather than a new mechanism

Commercially, the XR incremental thesis is whether physicians perceive meaningful value in real-world adherence and whether payers treat XR as interchangeable with IR or as a premium product.

What patents protect JAKAFI XR and how strong is the patent estate?

A durable investment thesis requires mapping three layers:

1. Active ingredient IP (ruxolitinib core chemistry)
2. Formulation and delivery IP (XR-specific compositions, coatings, release-rate control)
3. Use IP (method-of-use for specific indications, dosing schedules, titration, biomarkers)

How many patents cover JAKAFI XR in the US Orange Book?

A complete, accurate count requires Orange Book listing data tied to the specific NDC(s) for JAKAFI XR. Without that exact NDC-to-patent mapping for the XR product, any numeric count risks being incorrect.

Which patent families typically drive XR exclusivity?

For XR, the most consequential risks to generics usually come from:

• Extended-release formulation patents (polymer matrices, hydrophilic/hydrophobic blend systems, tablet or capsule architecture, osmotic release mechanisms, controlled dissolution specs)
• Manufacturing process patents (granulation, blending, coating parameters)
• Drug product specifications with release profiles tied to clinical dosing

For method-of-use, the risk is that competing applicants can file with a label carve-out, challenge only specific indications, or attempt to design around dosing or titration language.

What is the IP strategy investors should underwrite for XR?

Underwrite to:

• Composition-of-matter and formulation coverage that is difficult to design around
• At least one hard-to-at-risk claim that is XR-specific and appears in Orange Book listings
• Litigation posture that anticipates Paragraph IV challenges

When does JAKAFI XR lose exclusivity in the US and what are the key expiration dates?

The exclusivity timeline for any branded drug is governed by:

• Patent expiration dates for each listed patent family in the Orange Book
• Regulatory exclusivity (if applicable) such as data exclusivity and marketing exclusivity
• The timing of any Paragraph IV “first-filer” settlement or court outcomes

What is the earliest date for generic substitution risk?

Generic entry risk usually begins at:

• Patent expiration of the last relevant Orange Book-listed XR patent, or
• Settlement agreement effective dates that allow earlier launch, or
• Court rulings that invalidate or hold non-infringement for key claims

What investors should model

Model three scenarios:

• Base: exclusivity holds until the last relevant XR patent expires
• Patent-loss: key XR formulation or method-of-use claims are invalidated or found not infringed
• Settlement: pay-for-delay style resolution (if it occurs) that sets a launch date earlier than the latest patent

What generic entry risks exist for JAKAFI XR (Paragraph IV litigation scenarios)?

Paragraph IV risk is driven by:

• Number and quality of Orange Book-listed patents
• Whether there are XR-specific patents that are more difficult to design around
• Prior patterns of generic challenges in the ruxolitinib space (if any)

What is the typical structure of XR Paragraph IV strategies?

XR challengers often target:

• Formulation patents by using alternative release-rate technologies
• Manufacturing patents via different process steps
• Method-of-use patents by filing with limited labeling or designing around dosing language

What is the most likely claim type to face challenge?

In XR portfolios, the most frequently contested items are XR formulation and release-profile patents because they can be attacked through obviousness or lack of inventive step, and can be assessed through comparative release testing.

What is the investment impact if a Paragraph IV is filed?

A pending Paragraph IV can:

• Create anticipated revenue compression due to “at-risk” pricing behavior and wholesaler contracting
• Trigger retailer and payer tension as branded offers respond to expected discount pressure
• Raise legal and operational costs (defense spend and potential damages exposure)

What is the Orange Book status of JAKAFI XR and which patents are listed?

Orange Book status is the central diligence artifact for generic risk. For JAKAFI XR, the analysis must be NDC-specific:

• Each NDC lists patents with expiration dates
• Each patent has a regulatory basis (for example, method-of-use, formulation, etc.)

Without the exact Orange Book listing for the XR NDCs, an accurate table of patents and expiration dates cannot be produced.

How does JAKAFI XR compare with JAKAFI immediate-release (ruxolitinib IR) for competitive and IP risk?

Investors should compare:

• Demand overlap: whether XR cannibalizes IR or expands total addressable patients
• Payer interchangeability: formulary placement
• Residual patent life: whether XR has meaningful additional exclusivity beyond the parent IR

Competitive implications

If IR is losing exclusivity sooner than XR, XR may capture a “bridge” period. If IR has similar exclusivity, XR becomes a line-extension differentiation rather than a protection strategy.

Which companies are challenging JAKAFI XR and what litigation affects entry?

Paragraph IV litigation affects timing and probability of generic entry. The relevant diligence set includes:

• Defendants named in any ANDA litigation
• Parties that file or counter-file for stipulations
• Court dockets and settlement terms that define launch dates

A complete list of challengers and case outcomes requires specific docket and Orange Book/P-IV filing data tied to JAKAFI XR.

What manufacturing and IP barriers could delay a generic version of JAKAFI XR?

XR generics face higher technical barriers than IR because:

• Release kinetics must match therapeutic exposure windows
• FDA bioequivalence testing may require bridging across multiple strength levels
• Formulation changes can trigger differences in Cmax and Tmax that impact clinical interchangeability

What to diligence in real time (what drives timelines in litigation and approval)?

• Whether XR patents claim specific release mechanisms that are hard to replicate
• Whether manufacturing process claims are asserted
• Whether the ANDA applicant’s proposed formulation raises infringement risk via release profile similarity

What is the FDA regulatory pathway and approval status for JAKAFI XR?

Investment fundamentals require knowing where the drug sits in:

• Original approval pathway
• Supplement pathway for XR (if XR is a line extension)
• Labeling completeness for dosing schedule and titration language

For a US investor model, the key is whether the XR formulation has an exclusivity package that differs from the parent IR product and whether any new clinical data triggered additional marketing exclusivity.

What are the commercial fundamentals for JAKAFI XR (pricing, uptake, and revenue exposure)?

A credible investment model requires:

• Net price and rebate dynamics (premium versus interchangeability assumptions)
• Market share trajectory in myelofibrosis and PV
• Switching behavior from IR to XR (or vice versa)
• Persistence and adherence in real-world settings

How revenue exposure should be modeled

Revenue sensitivity typically increases as the drug approaches:

• The end of patent-protected periods
• Increased formulary pressure from payers
• The likelihood of generic discounting

Because XR differentiation can be payer-dependent, revenue exposure should incorporate:

• Formulary tier changes
• Patient assistance program constraints
• Contracting behavior by PBMs

How strong is JAKAFI XR’s competitive landscape versus other JAK inhibitors?

Ruxolitinib competes within the myelofibrosis and PV treatment ecosystem that includes other JAK inhibitors and combination strategies. The investment thesis for XR depends on:

• Whether competitor access expands faster than JAKAFI XR can expand share
• Whether clinicians shift to alternative regimens based on efficacy endpoints or tolerability
• Whether the XR dosing advantage affects long-term persistence enough to retain share

What settlement and launch timing scenarios should investors underwrite?

If Paragraph IV litigation occurs, typical settlement structures that matter for valuation are:

• “Workaround” settlements that allow launch at an agreed date
• Consent judgments tied to specific patent expiration dates
• Broad settlements that define both launch timing and labeling scope

An accurate settlement timeline requires the actual settlement or court orders tied to the XR-specific patents.

Key Takeaways

• The investment case for JAKAFI XR is driven by XR-specific exclusivity strength: formulation and release-profile IP is the most important generic barrier.
• Generic risk is modeled primarily through Orange Book-listed XR patents and any Paragraph IV filings tied to those patents, with timing set by expiration dates, litigation outcomes, or settlements.
• XR commercial value depends on payer interchangeability and whether XR adoption expands total ruxolitinib demand or mostly shifts patients from JAKAFI IR.
• Technical and IP barriers for XR generics are higher than for IR due to release kinetics requirements, raising the probability of delay if IP is robust.

FAQs

1. How do XR formulation patents change generic launch risk versus IR ruxolitinib?
2. What Orange Book patent categories (method-of-use vs formulation) usually drive ruxolitinib Paragraph IV outcomes?
3. How should investors model revenue when payers treat JAKAFI XR as substitutable with IR?
4. What does an “at-risk” generic launch scenario imply for branded pricing and net sales?
5. How do dosing titration label details affect design-around strategies for method-of-use challenges?

References (APA)

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed via FDA Orange Book database).
2. FDA. Labeling and approval information for ruxolitinib products (JAKAFI portfolio). (Accessed via Drugs@FDA).